ClinicalTrials.gg
WithdrawnNCT04834310Updated Sep 14, 2022

Postoperative Antibiotics Following Primary and Secondary Breast Augmentation

A Phase 4 interventional study of Cefazolin and Cephalexin in Surgical Site Infection, Capsular Contracture Associated With Breast Implant and Antibiotic Resistant Infection, sponsored by University of California, Los Angeles. Withdrawn. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-14.

Sponsored by University of California, Los Angeles · Phase 4, Interventional, and Treatment

How we know

Why this study was withdrawn
Do not have adequate funding to proceed with project.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Postoperative antibiotics are routinely used for implant-based breast augmentation at the investigators' institution. From 2017-2019, the investigators' institution has conducted approximately 270 primary and secondary breast augmentation procedures. Current plastic surgery literature does not provide recommendations for antibiotic prophylaxis following implant-based breast procedures. Despite controversy surrounding their utility during the postoperative course, postoperative antibiotics have become commonplace for many plastic surgeons. To date, strong scientific evidence supporting this practice is minimal and based largely on anecdotal evidence and limited studies, including poorly controlled retrospective and non-blinded prospective series. The goal of this study is to conduct a prospective randomized trial to assess whether extended antibiotic prophylaxis is necessary to prevent infection and long-term complications (e.g. capsular contracture) in patients undergoing augmentation mammoplasty with implants. The investigators' anticipate that extended antibiotic prophylaxis is not required. The rationale for discontinuing postoperative antibiotics is based on the following: (1) a single dose of preoperative intravenous antibiotics has been demonstrated to be sufficient prophylaxis for most breast surgeries and (2) there are patient safety concerns associated with prolonged antimicrobial use such as the development of resistant bacterial strains and clostridium-related infections. Concrete evidence that extended antibiotic prophylaxis is not required would encourage plastic surgeons to practice better antibiotic stewardship and help stymie the rise of drug-resistant organisms.

Read the detailed description

The investigators will perform a randomized, double-blinded, placebo-controlled trial at University of California Los Angeles Ronald Reagan Medical Center for patients undergoing primary and secondary breast augmentation between 2021-2025. The study will be added to a research registry before patient enrollment begins (i.e. www.clinicaltrials.gov) with study methods and results presented in the manner recommended by the CONSORT statement (available at www.consort-statement.org). The study will be designed as a non-inferiority trial with two parallel groups: the experimental group will receive an intraoperative dose of antibiotics followed by oral antibiotics for 5 days postoperatively (Cephalexin 500 mg four times per day or Clindamycin 300 mg four times per day, if Penicillin allergic) while the control group will receive an intraoperative dose of antibiotics (Cefazolin 1 g or 2 g, or Clindamycin 600 mg or 900 mg, if Penicillin allergic, higher doses provided if BMI > 30 kg/m2) followed by a placebo for 5 days postoperatively. Inclusion criteria will include: females and transgender females 18 years or older, patients undergoing primary breast augmentation, breast augmentation-mastopexy, and secondary breast augmentation with subglandular or submuscular implants. Secondary breast augmentation will include patients undergoing implant exchange secondary to capsular contracture and implant rupture. Exclusion criteria will include refusal or inability to consent, patients with biopsy-proven breast cancer, patients undergoing expander-based and autologous flap breast reconstruction following mastectomies, history of chest radiation, and the presence of active infection at the time of surgery. Patients who fail to take the placebos or antibiotics provided in the study for any reason, miss postoperative visits, and/or withdraw consent at any stage of the study will also be excluded.

For the analysis, the investigators plan to obtain hospital records with intraoperative procedural and postoperative clinic notes. Demographic information including gender, body mass index, comorbidities, smoking use, and prior breast surgeries will be collected and used for analysis. Power analysis for statistical equivalency using 8% infection rate yields a required sample size of 164 total patients, with planned 82 patients per group (i.e. experimental and control). This would provide 80 percent power at a significance level of 5 percent. The experimental group will consist of patients who receive an intraoperative dose of antibiotics followed by oral antibiotics for 5 days postoperatively. The control group includes patients who receive an intraoperative dose of antibiotics followed by a placebo for 5 days postoperatively. All medications and placebos will be formulated, compounded and dispensed by the University of California Los Angeles Investigational Research Pharmacy. An appointed Data and Safety Monitoring Board (DSMB) will monitor data and safety as recommended by the Investigational Review Board (IRB).

Antibiotics of choice include intravenous Cefazolin and oral Cephalexin. Intravenous and oral Clindamycin will be made available for subjects who are allergic to Penicillin. Subject allocation will be based on a 1:1 ratio for each group. Surgeons, nursing, and administrative staff will be responsible for recruitment. Prior to surgery, patients will be given a consent form to explain their involvement in the randomized trial. The consent process will inform the participant about details of the study and indicate participation is voluntary. They will also be given the risks, benefits, alternatives, and confidentiality of their information with proceeding with the study. Risks discussed with participants will include those associated with antibiotic use, including gastrointestinal symptoms, yeast infections, allergic reactions, development of resistant bacterial strains, and clostridium-related infections. Potential risks associated with no antibiotic use (i.e. placebo group), include infection. The interventions to protect those affected by these risks include hospital admission as detailed in the informed consent under the section "Office of the Human Research Protection Program (OHRPP)," and the option to opt out of the study. There are no medical benefits with participating in the study. However, participants will be informed that the results may contribute to the body of knowledge around postoperative antibiotics, and improve surgical protocols and postoperative care.

Randomization will be performed prior to surgery, and an assigned study coordinator will generate group assignments. Patients and surgeons will be blinded to the study before randomization takes place. However, surgeons will have access to information following medication dispensation in case any complications arise so that the provider can carry out appropriate interventions. Review of the rate of subject accrual and compliance will occur monthly during the recruitment phase. An interim analysis will be performed on the primary endpoint when 50% of patients have been randomized and have complete their 6-month follow up period. An independent statistician blinded to treatment allocation will perform the analyses. The statistician will report to DSMB who will have unmasked access to all data. Interim analysis will be used to inform stopping guidelines and trial adaptations (e.g. sample size re-estimation, alteration to the proportion of participants allocated to each study group, and changes to eligibility criteria). The Principal Investigator (PI) will be responsible for ensuring participants' safety on a daily basis. The DSMB will act in an advisory capacity to monitor participant safety, evaluate the progress of the study, and review procedures for maintaining the confidentiality, quality, management, and analysis of the data.

An adverse event will be any untoward medical occurrence in a subject without regard to the possibility of a causal relationship. Adverse events will be collected after the subject has provided consent and enrolled in the study. All adverse events occurring after entry into the study and up to their first postoperative visit will be recorded. A serious adverse event for this study is any untoward medical occurrence that is believed by the investigators to be causally related to study-drug and results in any of the following: life-threatening condition (i.e. immediate risk of death); severe or permanent disability, prolonged hospitalization, or a significant hazard as determined by the DSMB. Investigators will determine relatedness of an event to study based on a temporal relationship, as well as whether the event is unexpected or unexplained given the subject's clinical course, previous medical conditions, and concomitant medications. All adverse and severe events related to antibiotic use, including anaphylaxis requiring hospital admission and/or resulting in death, will be monitored through patient examination and chart review. Furthermore, events that meet criteria for an adverse and serious adverse will be reported to the IRB.

Six plastic surgeons will be involved in the study and will utilize a standardized surgical protocol. Initial follow up visits will be arranged within 1-2 weeks following surgery. Data on adherence to the treatment protocol will be collected monthly by research staff and reviewed quarterly by the Principal Investigator and the study statistician. Adherence of participants will be evaluated by inquiring about completion of antibiotics or placebos at each postoperative visit. During follow-up visits, inquiry will be made to assure patients receive their antibiotics or placebos. This information along with any post-operative complications will be transferred onto the patient's electronic medical record accordingly. Primary outcomes including surgical site infection, secondary outcomes (e.g. hematoma, seroma, wound dehiscence, implant loss, and capsular contracture), and antibiotic-related complications (e.g. antibiotic resistance, diarrhea, clostridium infection, yeast infections, rash, urinary tract infections, and gastrointestinal upset) will be documented. Surgical site infections will be determined by the surgeon however will be defined by the presence of the following signs and symptoms: fevers, purulent drainage, pain, tenderness, localized edema, heat, erythema, positive wound cultures, and leukocytosis. Study endpoints will include diagnosis of surgical site infection, development of secondary outcomes, and subject death or loss to follow-up. Follow-up will be continued until all patients have reached one of the study endpoints. Statistical tests will be performed by a statistician using statistical software and determined after enough data has been generated to perform preliminary analysis. Threats to study validity include under recruitment of subjects, subjects lost to follow-up, subject non-compliance, and subject crossovers. This study will be stopped prior to its completion if: the intervention is associated with adverse effects that call into question the safety of the intervention; difficulty in study recruitment or retention will significantly impact the ability to evaluate the study endpoints; any new information becomes available during the trial that necessitates stopping the trial; or other situations occur that might warrant stopping the trial.

02

Conditions studied

  • Surgical Site Infection
  • Capsular Contracture Associated With Breast Implant
  • Antibiotic Resistant Infection
  • Antibiotic Side Effect
03

In context

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,171 studies on the registry; 195 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 year or older
  • Participants undergoing primary breast augmentation with subglandular or submuscular implants
  • Participants undergoing breast augmentation-mastopexy with subglandular or submuscular implants
  • Participants undergoing secondary breast augmentation with subglandular or submuscular implants (i.e. patients undergoing implant exchange secondary to capsular contracture and implant rupture)

Exclusion criteria

Exclusion Criteria:

  • Refusal or inability to obtain consent from participants
  • Participants with -proven breast cancer
  • Participants undergoing expander-based breast reconstruction
  • Participants undergoing autologous flap breast reconstruction
  • Participants with history of chest radiation
  • Participants with active infection at the time of surgery
  • Participants who fail to take the placebos or antibiotics provided in the study for any reason
  • Participants who miss postoperative visits
  • Participants who withdraw consent at any stage of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Intraoperative and Postoperative Antibiotics

    The experimental group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by oral antibiotics for 5 days postoperatively.

    Drug: Cefazolin · Drug: Cephalexin

  • Placebo comparator
    Intraoperative Antibiotics and Placebo

    The control group will receive an intraoperative dose of antibiotics, which is standard protocol at our institution, followed by a placebo for 5 days postoperatively

    Drug: Cefazolin · Other: Placebo

Interventions

  • All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.

    Also known as: Ancef, Clindamycin, Cleocin

  • The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.

    Also known as: Keflex, Clindamycin, Cleocin

  • OtherPlacebo

    The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.

06

What researchers measure

Primary outcomes

  1. Number of participants with surgical site infection

    Surgical site infections will be determined by the surgeon however will be defined by the presence of the following signs and symptoms: fevers, purulent drainage, pain, tenderness, localized edema, heat, erythema, positive wound cultures, and leukocytosis.

    Time frame: 365 days following surgery

Secondary outcomes

  1. Number of participants with hematoma

    Fluid collection consisting of blood secondary to procedure identified by clinical exam and/or ultrasound.

    Time frame: 365 days following surgery

  2. Number of participants with seroma

    Fluid collection consisting of serous fluid secondary to procedure identified by clinical exam and/or ultrasound.

    Time frame: 365 days following surgery

  3. Number of participants with wound dehiscence

    Any re-opening of surgical incision following procedure which was closed primarily.

    Time frame: 365 days following surgery

  4. Number of participants with implant loss

    Extrusion of implant or condition resulting in implant removal secondary to procedure.

    Time frame: 365 days following surgery

  5. Number of participants with antibiotic-related complications

    Diarrhea, clostridium infection, yeast infections, rash, urinary tract infections, and gastrointestinal upset

    Time frame: 365 days following surgery

  6. Number of participants with antibiotic resistance

    Local wound infections and fluid collections will be cultured and sent for identification and susceptibility. Resistant strains will be documented and treated with alternative antibiotics.

    Time frame: 365 days following surgery

Other outcomes

  1. Patient compliance

    Patients will be asked during the first postoperative visit if they had taken their placebos or antibiotics.

    Time frame: 365 days following surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chopra K, Gowda AU, McNichols CHL, Brown EN, Slezak S, Rasko Y. Antimicrobial Prophylaxis Practice Patterns in Breast Augmentation: A National Survey of Current Practice. Ann Plast Surg. 2017 Jun;78(6):629-632. doi: 10.1097/SAP.0000000000000942. PubMed 27922894 ↗
  • Hardwicke JT, Bechar J, Skillman JM. Are systemic antibiotics indicated in aesthetic breast surgery? A systematic review of the literature. Plast Reconstr Surg. 2013 Jun;131(6):1395-1403. doi: 10.1097/PRS.0b013e31828bd752. PubMed 23416440 ↗
  • Keramidas E, Lymperopoulos NS, Rodopoulou S. Is antibiotic prophylaxis in breast augmentation necessary? A prospective study. Plast Surg (Oakv). 2016 Fall;24(3):195-198. doi: 10.4172/plastic-surgery.1000976. Epub 2016 Aug 19. PubMed 28439510 ↗
  • LeRoy J, Given KS. Wound infection in breast augmentation: the role of prophylactic perioperative antibiotics. Aesthetic Plast Surg. 1991 Fall;15(4):303-5. doi: 10.1007/BF02273877. PubMed 1950803 ↗
  • Mirzabeigi MN, Mericli AF, Ortlip T, Tuma GA, Copit SE, Fox JW 4th, Moore JH Jr. Evaluating the role of postoperative prophylactic antibiotics in primary and secondary breast augmentation: a retrospective review. Aesthet Surg J. 2012 Jan;32(1):61-8. doi: 10.1177/1090820X11430830. PubMed 22231414 ↗
  • Gylbert L, Asplund O, Berggren A, Jurell G, Ransjo U, Ostrup L. Preoperative antibiotics and capsular contracture in augmentation mammaplasty. Plast Reconstr Surg. 1990 Aug;86(2):260-7; discussion 268-9. PubMed 2195567 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2021; primary completion for May 2024, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2021
First posted
Apr 8, 2021
StartEst.
Apr 1, 2021
Primary completionEst.
May 30, 2024
CompletionEst.
Jul 30, 2024
Last update
Sep 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04834310
Responsible party
Karie Villanueva, MD (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Apr 8, 2021
Start date
Apr 1, 2021 (estimated)
Primary completion
May 30, 2024 (estimated)
Completion
Jul 30, 2024 (estimated)
Last update
Sep 14, 2022

Study contacts

Karie Villanueva, MD
principal investigator · University of California, Los Angeles
Jaco Festekjian, MD
study chair · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cephalexin

Start the discussion